Softwr

Healthcare · head to head

Lunit vs RXNT

Lunit logo

Lunit

Healthcare

FDA cleared and CE marked AI for mammography, tomosynthesis and chest radiography

From
On request
Rated
-
Full reviewWebsite
RXNT logo

RXNT

Healthcare

Cloud practice management and EHR software with a la carte modules

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Lunit the regulatory permission differs by product and by region, and INSIGHT Risk has been filed with the FDA but not cleared, so a buyer who reads a corporate press release rather than the specific clearance for their product and jurisdiction will plan a deployment they cannot legally run.; RXNT specific pricing tiers not displayed; plans reference starting at $118/month
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Lunit and RXNT actually diverge.

Attributes where Lunit and RXNT differ
AttributeLunitRXNT
Pricing modelquotesubscription

Identical on both: starting price (On request), free tier (No), platforms (Web), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Lunit

  • Lunit INSIGHT MMG
  • Lunit INSIGHT DBT
  • Lunit INSIGHT CXR
  • Volpara density assessment
  • Volpara RiskPathways
  • Volpara dose tracking
  • PACS and mammography workstation integration

Only in RXNT

Nothing recorded that Lunit does not also cover.

What people use each for

The jobs each tool is most often brought in to do.

Lunit

  • A national breast screening programme evaluating AI as a second reader to reduce double reading workload where two human readers are currently mandatednot RXNT
  • A breast centre that moved to tomosynthesis and now has reading times it cannot staff, wanting detection support on DBT specificallynot RXNT
  • An American breast imaging centre needing automated volumetric density assessment to meet patient density notification requirements, which is what Volpara is bought fornot RXNT
  • A tuberculosis or lung screening programme in a high volume, radiologist scarce setting using chest radiography triage to prioritise filmsnot RXNT

RXNT

  • Running entire medical practices from single integrated platformnot Lunit
  • Managing electronic prescriptions including controlled Schedule II-V drugsnot Lunit
  • Streamlining billing and claims management with unlimited claim processingnot Lunit
  • Supporting specialty workflows for mental health and hospice providersnot Lunit
  • Capturing appointment reminders and patient billing through patient portalnot Lunit

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Lunit

  • The regulatory permission differs by product and by region, and INSIGHT Risk has been filed with the FDA but not cleared, so a buyer who reads a corporate press release rather than the specific clearance for their product and jurisdiction will plan a deployment they cannot legally run.
  • Detection AI changes recall rates in screening, and the downstream cost of additional diagnostic workup lands on the programme rather than on the software budget, which is the cost most screening business cases omit.
  • Performance is sensitive to the mammography vendor and acquisition protocol, so published results from a Hologic estate do not transfer to a GE or Siemens estate without local validation the buyer must fund.
  • MMG, DBT and CXR are licensed separately and Volpara modules are separate again, so a breast centre wanting detection, density and risk pathways is assembling four line items rather than buying one product.
  • Using AI as a replacement for one of two human readers is a workforce and liability decision that regulators and professional bodies treat differently in each country, so the saving that justifies the purchase may not be permitted where you operate.

RXNT

  • Specific pricing tiers not displayed; plans reference starting at $118/month
  • E-prescribing only available with yearly subscription
  • Requires contacting sales for personalized pricing

Pricing, plan by plan

Lunit

On request
  • Lunit INSIGHT$undefined/year
    • Priced per study or per annual examination volume by product
    • MMG, DBT and CXR licensed separately
    • Volpara density and RiskPathways modules quoted separately

RXNT

On request

No published plan breakdown. See the RXNT review.

Which should you pick?

Choose Lunit if

  • You need lunit insight mmg.
  • You also want lunit insight dbt.
Lunit review

Choose RXNT if

Nothing in the data separates RXNT from Lunit on the points above - pick on price and on how each one feels to use.

RXNT review

Questions people ask

Is Lunit or RXNT better?
Neither clearly leads. Lunit starts at On request and RXNT at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Lunit or RXNT?
Lunit starts at On request and RXNT at On request.
Does Lunit or RXNT run on more platforms?
Both run on Web, so platform support will not decide this one for you.
What is Lunit best used for?
Lunit is most often used for a national breast screening programme evaluating ai as a second reader to reduce double reading workload where two human readers are currently mandated, a breast centre that moved to tomosynthesis and now has reading times it cannot staff, wanting detection support on dbt specifically, an american breast imaging centre needing automated volumetric density assessment to meet patient density notification requirements, which is what volpara is bought for, a tuberculosis or lung screening programme in a high volume, radiologist scarce setting using chest radiography triage to prioritise films. Of those, a national breast screening programme evaluating ai as a second reader to reduce double reading workload where two human readers are currently mandated and a breast centre that moved to tomosynthesis and now has reading times it cannot staff, wanting detection support on dbt specifically are not what RXNT is typically brought in for.
What can Lunit do that RXNT cannot?
Lunit covers Lunit INSIGHT MMG, Lunit INSIGHT DBT, Lunit INSIGHT CXR, Volpara density assessment.

Answered from the vendors’ own pages

Lunit: Is Lunit FDA cleared?

Yes for specific products. INSIGHT MMG, INSIGHT DBT and INSIGHT CXR Triage hold FDA 510(k) clearances. INSIGHT Risk, the five year risk prediction model, has been filed but was not cleared at the time of writing.

RXNT: What is RXNT's pricing model?

RXNT offers a-la-carte and bundled subscription options with monthly or annual billing. Annual subscriptions receive a 10% discount. Pricing starts at $118/month, though specific tier pricing is not displayed.

Source
Lunit: Can Lunit replace a second human reader in screening?

That depends entirely on your jurisdiction and professional body guidance, not on the software. The CE mark permits clinical use; it does not authorise a workforce model.

RXNT: What are the additional costs for RXNT?

RXNT charges $85 per year for EPCS (Electronic Prescribing of Controlled Substances) including ID proofing and biometric authentication. Non-prescribing staff also have license fees, and data imports and extended onboarding are available at additional cost.

Source
Lunit: What did the Volpara acquisition add?

Volumetric breast density measurement, dose tracking and RiskPathways high risk programme management, which are the things American breast centres buy for density notification compliance rather than for detection.

RXNT: What onboarding support does RXNT provide?

RXNT includes 45 days of onboarding with the EHR Bundle and 60 days with the Practice Management and Full Suite bundles.

Source
Lunit: Is pricing published?

No. It is quoted per study or per annual volume, by product, with on premises and cloud priced differently.

Share

Related pages

More on Lunit

More on RXNT

Keep looking

Other head to heads